Compare NBBK & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NBBK | SGMT |
|---|---|---|
| Founded | 1892 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 926.5M | 761.6M |
| IPO Year | 2023 | 2021 |
| Metric | NBBK | SGMT |
|---|---|---|
| Price | $22.60 | $9.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $25.00 | ★ $27.91 |
| AVG Volume (30 Days) | 246.2K | ★ 1.2M |
| Earning Date | 10-15-2026 | 11-16-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | ★ 25.23 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $9.75 | N/A |
| P/E Ratio | $24.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.54 | $4.50 |
| 52 Week High | $23.47 | $11.45 |
| Indicator | NBBK | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 51.22 |
| Support Level | $21.38 | $8.54 |
| Resistance Level | $22.81 | $11.33 |
| Average True Range (ATR) | 0.63 | 0.62 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 63.66 | 65.25 |
NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.